15 January 2007: GW Pharmaceuticals plc (“GW”) today announces preliminary results of two Phase III studies of Sativex®, its cannabinoid spray medicine, in peripheral neuropathic pain. These studies are part of a programme to generate data for the future expansion of the use of Sativex in Europe beyond Multiple Sclerosis (MS) into other pain conditions.
